| Rheumatoid Arthritis
Otrexup vs Simponi ARIA
Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.Deep comparison between: Otrexup vs Simponi Aria with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSimponi Aria has a higher rate of injection site reactions vs Otrexup based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Simponi Aria but not Otrexup, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Otrexup
Simponi Aria
At A Glance
SC injection
Once weekly
Folate analog metabolic inhibitor
IV infusion
Every 8 weeks
TNF-alpha inhibitor
Indications
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Psoriasis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Juvenile polyarthritis
Dosing
Rheumatoid Arthritis 7.5 mg SC once weekly; adjust dose gradually; doses greater than 20 mg/week associated with significant increase in serious toxic reactions in adults.
Juvenile polyarthritis 10 mg/m2 SC once weekly; adjust dose gradually.
Psoriasis 10 to 25 mg SC once weekly; do not exceed 30 mg/week; reduce to lowest effective dose once optimal response is achieved.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 2 mg/kg intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter; RA patients must receive concomitant methotrexate.
Juvenile polyarthritis 80 mg/m2 intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter (body surface area-based dosing for patients 2 years of age and older).
Contraindications
- Pregnancy
- Alcoholism, alcoholic liver disease, or other chronic liver disease
- Overt or laboratory evidence of immunodeficiency syndromes
- Preexisting blood dyscrasias, such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia
- Known hypersensitivity to methotrexate
—
Adverse Reactions
Most common (>=10%) Elevated liver function tests, nausea/vomiting, ulcerative stomatitis, leukopenia, abdominal distress
Serious Bone marrow suppression, hepatotoxicity, interstitial pneumonitis, opportunistic infections, embryo-fetal toxicity, renal failure, pulmonary fibrosis
Postmarketing Toxic epidermal necrolysis, Stevens-Johnson syndrome, anaphylactoid reactions, reversible lymphoma, skin necrosis
Most common (>=1%) Upper respiratory tract infection, viral infections, bacterial infections, bronchitis, hypertension, rash, pyrexia, leukopenia
Serious Serious infections (sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis), malignancies, liver enzyme elevations, infusion reactions
Postmarketing Infusion-related reactions, melanoma, Merkel cell carcinoma, anaphylactic reaction, sarcoidosis, interstitial lung disease, skin exfoliation, lichenoid reactions, bullous skin reactions
Pharmacology
Methotrexate inhibits dihydrofolic acid reductase, preventing reduction of dihydrofolates to tetrahydrofolates and thereby interfering with DNA synthesis, repair, and cellular replication; in RA the mechanism is unknown but may affect immune function, and in psoriasis it exploits the markedly increased rate of epithelial cell proliferation.
Golimumab is a human monoclonal antibody (TNF-alpha inhibitor) that binds to both the soluble and transmembrane bioactive forms of human TNF-alpha, preventing receptor binding and inhibiting TNF-alpha biological activity, a key mediator of articular inflammation in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Otrexup
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Simponi Aria
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
UnitedHealthcare
Otrexup
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Simponi Aria
- Covered on 4 commercial plans
- PA (3/8) · Step Therapy (0/8) · Qty limit (3/8)
Humana
Otrexup
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Simponi Aria
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Otrexup.
Cost estimate not availableAssistance Fund: Ankylosing Spondylitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OtrexupView full Otrexup profile
Simponi AriaView full Simponi Aria profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.